Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
CytoSorbents Corp (CTSO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$4.60+0.88%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CTSO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain Nasdaq listing compliance | A primary condition in CytoSorbents Corp's published investment case. The stated target is No delisting or transfer of listing. | Under Pressure | Company is delisted or transferred from Nasdaq | Market value < $35M target; Bid price $4.56 vs $1.00 min Nasdaq delisting notice for market value < $35M. Bid price $4.56 exceeds $1.00 minimum. No delisting executed yet. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making healthcare company with a turnaround-style long-term thesis. Its status is watch: recent financial performance trails its industry cohort, and the overall signal has shifted from mildly favorable to mixed.
CTSO is valued at a substantial premium to peers, and the valuation model has low confidence. The evidence flags the valuation as expensive without the full combination of expensive, weak, and turbulent conditions, but it does not establish a clear expectations cushion.
Near term, two recent earnings misses and a stated risk of another weak report make execution uncertain. Across 2026-Q1 to Q2, revenue and gross profit rose while operating losses narrowed, supporting management’s stated goal of operating cash-flow breakeven in H2 2026. CytoSorb sales have edged up, while the DrugSorb-ATR regulatory path remains pending after the original application was denied.
The multi-year thesis hinges on reaching operating cash-flow breakeven and turning modest CytoSorb progress into sustainable profitable growth. A guidance cut or continued labor-market weakness would add pressure, while stronger results and guidance from healthcare peers could support the sector backdrop. DrugSorb-ATR’s planned new submission for late 2026 or early 2027 is another key uncertainty.
Over the next 1 to 3 years, the case rests on measurable progress in cash flow and product growth, but recent misses, high risk, and unresolved regulatory work leave the thesis fragile. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| CytoSorbents aims to reach operating cash flow breakeven in the second half of 2026. |
| Improving |
| operating cash flow remains negative through H2 2026 |
Cash from operations: $-1.745M FY2026-Q2; GAAP. Published target: >= $0 operating cash flow. Target period is not explicitly aligned with this observation. Aug 6, 2026-1,745,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Filling big gaps in country coverage with 3 - 5 new sales rep hires now into early 2027.” “Meanwhile, we have continued to make operational improvements and cost reductions and believe these actions will continue to drive improvements in the coming quarters to support our goal of achieving operating cash flow breakeven in the second half of this year.”” Operating income was $-2.638 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Sustain revenue growth near 17% in FY26 | A primary condition in CytoSorbents Corp's published investment case. The stated target is >= 17% YoY revenue growth. | Broken | revenue growth falls below 10% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.03 → $-0.68 · observed estimates
$0.05B → $0.04B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-07-25 | $0.00 | $47,123,000 | 1 / 1 |
| 2026-07-26 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-07-27 | $0.00 | $47,123,000 | 1 / 1 |
| 2026-07-28 | $0.00 | $47,123,000 | 1 / 1 |
| 2026-07-29 | $0.00 | $47,123,000 | 1 / 1 |
| 2026-07-30 | $0.00 | $47,123,000 | 1 / 1 |
| 2026-07-31 | $0.00 | $47,123,000 | 1 / 1 |
| 2026-08-01 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-02 | $0.00 | $47,123,000 | 1 / 1 |
| 2026-08-03 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-04 | $0.00 | $47,123,000 | 1 / 1 |
| 2026-08-05 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-06 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-07 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-08 | $0.00 | $47,123,000 | 1 / 1 |
| 2026-08-09 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-10 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-11 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-12 | $0.00 | $47,123,000 | 1 / 1 |
| 2026-08-13 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-14 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-15 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-16 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-17 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-18 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-19 | $0.03 | $47,123,000 | 1 / 1 |
| 2026-08-20 | $-0.04 | $47,100,000 | 1 / 1 |
| 2026-08-21 | $-0.04 | $47,100,000 | 1 / 2 |
| 2026-08-22 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-08-23 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-08-24 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-08-25 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-08-26 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-08-27 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-08-28 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-08-29 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-08-30 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-08-31 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-09-01 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-09-02 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-09-03 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-09-04 | $-0.04 | $47,100,000 | 2 / 2 |
| 2026-09-05 | $-0.04 | $43,550,000 | 2 / 2 |
| 2026-09-06 | $-0.04 | $43,550,000 | 2 / 2 |
| 2026-09-07 | $-0.04 | $43,550,000 | 2 / 2 |
| 2026-09-08 | $-0.04 | $43,550,000 | 2 / 2 |
| 2026-09-09 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-10 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-11 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-12 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-13 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-14 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-15 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-16 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-17 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-18 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-19 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-20 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-21 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-22 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-23 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-24 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-25 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-26 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-27 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-28 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-29 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-09-30 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-01 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-02 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-03 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-04 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-05 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-06 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-07 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-08 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-09 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-10 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-11 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-12 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-13 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-14 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-15 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-16 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-17 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-18 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-19 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-20 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-21 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-22 | $-0.90 | $43,550,000 | 2 / 2 |
| 2026-10-23 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-10-24 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-10-25 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-10-26 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-10-27 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-10-28 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-10-29 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-10-30 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-10-31 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-11-01 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-11-02 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-11-03 | $-0.68 | $43,400,000 | 2 / 2 |
| 2026-11-04 | $-0.68 | $43,400,000 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.